Mercury Laboratories Limited (BOM:538964)

India · Delayed Price · Currency is INR

803.00

-21.00 (-2.55%)

At close: Jul 8, 2026

-6.50% (1Y)

Market Cap	963.60M -4.2%
Revenue (ttm)	759.37M +1.1%
Net Income	48.34M +53.7%
EPS	40.28 +53.7%
Shares Out	1.20M
PE Ratio	19.94
Forward PE	n/a
Dividend	3.50 (0.42%)
Ex-Dividend Date	Sep 21, 2026

Volume	12
Open	824.00
Previous Close	824.00
Day's Range	802.00 - 824.00
52-Week Range	620.55 - 976.00
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 3, 2026

About Mercury Laboratories

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergi... [Read more]

Industry Pharmaceutical Preparations

Founded 1962

Employees 503

Stock Exchange Bombay Stock Exchange

Ticker Symbol 538964

Full Company Profile

Financial Performance

In fiscal year 2026, Mercury Laboratories's revenue was 759.37 million, an increase of 1.11% compared to the previous year's 751.01 million. Earnings were 48.34 million, an increase of 53.71%.

Financial Statements